ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

ClinicalTrials.gov ID: NCT00265382

Public ClinicalTrials.gov record NCT00265382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

Study identification

NCT ID
NCT00265382
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
221 participants

Conditions and interventions

Conditions

Interventions

  • Ziprasidone oral capsules Drug

Drug

Eligibility (public fields only)

Age range
13 Years to 17 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2006
Primary completion
May 31, 2009
Completion
May 31, 2009
Last update posted
Mar 2, 2021

2006 – 2009

United States locations

U.S. sites
26
U.S. states
13
U.S. cities
21
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35205
Pfizer Investigational Site Birmingham Alabama 35294-4400
Pfizer Investigational Site Birmingham Alabama 35294
Pfizer Investigational Site San Diego California 92123-2717
Pfizer Investigational Site Denver Colorado 80218
Pfizer Investigational Site Washington D.C. District of Columbia 20010
Pfizer Investigational Site Altamonte Springs Florida 32701
Pfizer Investigational Site Orange City Florida 32763
Pfizer Investigational Site Smyrna Georgia 30080
Pfizer Investigational Site Tucker Georgia 30084
Pfizer Investigational Site Des Plaines Illinois 60016
Pfizer Investigational Site Oakbrook Terrace Illinois 60181
Pfizer Investigational Site Schaumburg Illinois 60194
Pfizer Investigational Site Clinton Township Michigan 48038
Pfizer Investigational Site Bridgeton Missouri 63044-2588
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Buffalo New York 14215
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Cincinnati Ohio 45224
Pfizer Investigational Site Cincinnati Ohio 45229
Pfizer Investigational Site Cincinnati Ohio 45267-0559
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Oklahoma City Oklahoma 73101
Pfizer Investigational Site Oklahoma City Oklahoma 73116
Pfizer Investigational Site Bothell Washington 98011
Pfizer Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00265382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 2, 2021 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00265382 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →